Loperamide/simethicone Loperamide/simethicone Loperamide/simethicone is combination medication marketed under the trade name Imodium Multi-Symptom Relief (formerly Imodium A-D Advanced) used to treat diarrhea and gas simultaneously. It is manufactured by the McNeil Consumer Healthcare Division of McNeil PPC, Inc. Loperamide is a μ-opioid receptor agonist that works in the intestines. Although it is an opioid, it has no effects on the central nervous system. It reduces diarrhea by slowing the transit time of contents through the intestinal tract thereby allowing more water to be reabsorbed from the intestinal lumen. Simethicone reduces gas by allowing smaller gas bubbles to coalesce into larger bubbles
Loperamide 2-mg tablets was added to WHO Model List of Essential Medicines. It is sold as a generic medication and is not very expensive. The wholesale cost in the developing world is about US$0.004 to 0.040 a dose. In August 2016, the US retail cost is about US$0.31 per dose. In 2016, Imodium was one of the biggest-selling branded over-the-counter medications sold in Great Britain, with sales of £32.7 million. Loperamide was originally marketed as Imodium, and many generic brands are sold. Loperamide has typically been deemed to have a relatively low risk of misuse. In 2012, no reports of loperamide